HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration.

AuthorsSanjeewa Wickremasinghe, Farshad Abedi, Sukhpal S Sandhu, Robyn Guymer
JournalClinical & experimental ophthalmology (Clin Exp Ophthalmol) Vol. 41 Issue 8 Pg. 723-6 (Nov 2013) ISSN: 1442-9071 [Electronic] Australia
PMID24152187 (Publication Type: Editorial)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Bevacizumab
  • Drug Administration Schedule
  • Humans
  • Ranibizumab
  • Retreatment
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Wet Macular Degeneration (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: